MCT-1 oncogene downregulates p53 and destabilizes genome structure in the response to DNA double-strand damage

DNA Repair

Volumn 6, Issue 9, 2007, Pages 1319-1332

  Hsu, Hsin Ling ^a   Choy, Chik On ^a   Kasiappan, Ravi ^a   Shih, Hung Ju ^a   Sawyer, Jeffrey R ^b   Shu, Chung Li ^a   Chu, Kang Lin ^a   Chen, Yi Rong ^a   Hsu, Hsin Fen ^a   Gartenhaus, Ronald B ^c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Cell cycle checkpoint; Chromosomal instability; MAPK; MCT 1 oncogene; p21; p53

Indexed keywords

DOUBLE STRANDED DNA; ETOPOSIDE; HISTONE H2AX; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCARBOXYLATE TRANSPORTER 1; PROTEIN P21; PROTEIN P53;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHROMOSOME 14; CHROMOSOME 6; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA STRAND BREAKAGE; DOWN REGULATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GAMMA IRRADIATION; GENE STRUCTURE; GENOME ANALYSIS; GENOMICS; GENOTOXICITY; HUMAN; HUMAN CELL; KARYOTYPE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; UBIQUITINATION;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELLS, CULTURED; CHROMOSOMAL INSTABILITY; COMET ASSAY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DNA REPLICATION; DOWN-REGULATION; FIBROBLASTS; G1 PHASE; G2 PHASE; HISTONES; HUMANS; KARYOTYPING; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; ONCOGENE PROTEINS; S PHASE; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34547842074     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2007.02.028     Document Type: Article

References (64)

1. Rabbitts T.H. Chromosomal translocations in human cancer. Nature 372 (1994) 143-149 (Review)
2. Gollin S.M. Chromosomal instability. Curr. Opin. Oncol. 16 (2004) 25-31 (Review)
3. Nojima H. G1 and S-phase checkpoints, chromosome instability, and cancer. Methods Mol. Biol. 280 (2004) 3-49 (Review)
4. Michor F., Iwasa Y., Vogelstein B., Lengauer C., and Nowak M.A. Can chromosomal instability initiate tumorigenesis?. Semin. Cancer Biol. 15 (2005) 43-49 (Review)
5. Draviam V.M., Xie S., and Sorger P.K. Chromosome segregation and genomic stability. Curr. Opin. Genet. Dev. 14 (2004) 120-125 (Review)
6. Gollin S.M. Mechanisms leading to chromosomal instability. Semin. Cancer Biol. 15 (2005) 33-42 (Review)
7. Schwartz D., and Rotter V. p53-Dependent cell cycle control: response to genotoxic stress. Semin. Cancer Biol. 8 (1998) 325-336 (Review)
8. Taylor W.R., and Stark G.R. Regulation of the G2/M transition by p53. Oncogene 20 (2001) 1803-1815 (Review)
9. Gomez-Lazaro M., Fernandez-Gomez F.J., and Jordan J. p53: twenty-five years understanding the mechanism of genome protection. J. Physiol. Biochem. 60 (2004) 287-307 (Review)
10. Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54 (1994) 4855-4878
11. Lim B.H., Soong R., Grieu F., Robbins P.D., House A.K., and Iacopetta B.J. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int. J. Cancer 69 (1996) 200-204
12. Tomizawa Y., Kohno T., Fujita T., Kiyama M., Saito R., Noguchi M., Matsuno Y., Hirohashi S., Yamaguchi N., Nakajima T., and Yokota J. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 18 (1999) 1007-1014
13. Niklinski J., Niklinska W., Laudanski J., Chyczewska E., and Chyczewski L. Prognostic molecular markers in non-small cell lung cancer. Lung Cancer 2 (2001) S53-S58 (Review)
14. Leroy K., Haioun C., Lepage E., Le Metayer N., Berger F., Labouyrie E., Meignin V., Petit B., Bastard C., Salles G., Gisselbrecht C., Reyes F., Gaulard P., and Groupe d'Etude des Lymphomes de l'Adulte. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann. Oncol. 13 (2002) 1108-1115
15. Motoyama N., and Naka K. DNA damage tumor suppressor genes and genomic instability. Curr. Opin. Genet. Dev. 14 (2004) 11-16 (Review)
16. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
17. Yang Y., Li C.C., and Weissman A.M. Regulating the p53 system through ubiquitination. Oncogene 23 (2004) 2096-2106 (Review)
18. Brooks C.L., and Gu W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21 (2006) 307-315 (Review)
19. Mayo L.D., and Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 11598-11603
20. Mayo L.D., and Donner D.B. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. 27 (2002) 462-467 (Review)
21. Zhou B.P., and Hung M.C. Novel targets of Akt, p21(Cipl/WAF1), and MDM2. Semin. Oncol. 29 (2002) 62-70
22. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., and Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by AKT1-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell. Biol. 3 (2001) 245-252
23. Feng J., Tamaskovic R., Yang Z., Brazil D.P., Merlo A., Hess D., and Hemmings B.A. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J. Biol. Chem. 279 (2004) 35510-35517
24. Ries S., Biederer C., Woods D., Shifman O., Shirasawa S., Sasazuki T., McMahon M., Oren M., and McCormick F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103 (2000) 321-330
25. Phelps M., Phillips A., Darley M., and Blaydes J.P. MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. J. Biol. Chem. 280 (2005) 16651-16658
26. Wu X., Bayle J.H., Olson D., and Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7 (1993) 1126-1132
27. Arriola E.L., Lopez A.R., and Chresta C.M. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Oncogene 18 (1999) 1081-1091
28. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
29. Harper J.W., Adami G.R., Wei N., Keyomarsi K., and Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 (1993) 805-816
30. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704
31. Weiss R.H. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4 (2003) 425-429 (Review)
32. Yu J., and Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun. 331 (2005) 851-858 (Review)
33. Leake R. The cell cycle and regulation of cancer cell growth. Ann. N Y Acad. Sci. 784 (1996) 252-262 (Review)
34. Wahl G.M., Linke S.P., Paulson T.G., and Huang L.C. Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv. 29 (1997) 183-219 (Review)
35. Reed J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17 (1999) 2941-2953 (Review)
36. Dash B.C., and El-Deiry W.S. Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol. Biol. 280 (2004) 99-161 (Review)
37. Dasika G.K., Lin S.C., Zhao S., Sung P., Tomkinson A., and Lee E.Y. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18 (1999) 7883-7899 (Review)
38. van Gent D.C., Hoeijmakers J.H., and Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat. Rev. Genet. 2 (2001) 196-206 (Review)
39. O'Driscoll M., and Jeggo P.A. The role of double-strand break repair-insights from human genetics. Nat. Rev. Genet. 7 (2006) 45-54 (Review)
40. Sharpless N.E., Ferguson D.O., O'Hagan R.C., Castrillon D.H., Lee C., Farazi P.A., Alson S., Fleming J., Morton C.C., Frank K., Chin L., Alt F.W., and DePinho R.A. Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. Mol. Cell 8 (2001) 1187-1196
41. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., Orntoft T., Lukas J., and Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
42. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio Jr. R.A., Kastrinakis N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., and Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 (2005) 907-913
43. Hsu H.L., Shi B., and Gartenhaus R.B. The MCT-1 oncogene product impairs cell cycle checkpoint control and transforms human mammary epithelial cells. Oncogene 24 (2005) 4956-4964
44. Dierov J., Prosniak M., Gallia G., and Gartenhaus R.B. Increased G1 cyclin/cdk activity in cells overexpressing the candidate oncogene, MCT-1. J. Cell. Biochem. 74 (1999) 544-550
45. Prosniak M., Dierov J., Okami K., Tilton B., Jameson B., Sawaya B.E., and Gartenhaus R.B. A novel candidate oncogene, MCT-1, is involved in cell cycle progression. Cancer Res. 58 (1998) 4233-4237
46. Shi B., Hsu H.L., Evens A.M., Gordon L.I., and Gartenhaus R.B. Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. Blood 102 (2003) 297-302
47. Levenson A.S., Thurn K.E., Simons L.A., Veliceasa D., Jarrett J., Osipo C., Jordan V.C., Volpert O.V., Satcher Jr. R.L., and Gartenhaus R.B. MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. Cancer Res. 65 (2005) 10651-10656
48. Baldwin E.L., and Osheroff N. Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agent 5 (2005) 363-372 (Review)
49. Burger R.M. Cleavage of nucleic acids by bleomycin. Chem. Res. 98 (1998) 1153-1170
50. Ostrakhovitch E.A., and Cherian M.G. Inhibition of extracellular signal regulated kinase (ERK) leads to apoptosis inducing factor (AIF) mediated apoptosis in epithelial breast cancer cells: the lack of effect of ERK in p53 mediated copper induced apoptosis. J. Cell. Biochem. 95 (2005) 1120-1134
51. Knudsen K.E., Booth D., Naderi S., Sever-Chroneos Z., Fribourg A.F., Hunton I.C., Feramisco J.R., Wang J.Y., and Knudsen E.S. RB-dependent S-phase response to DNA damage. Mol. Cell. Biol. 20 (2000) 7751-7763
52. Kao G.D., McKenna W.G., and Yen T.J. Detection of repair activity during the DNA damage-induced G2 delay in human cancer cells. Oncogene 20 (2001) 3486-3496
53. Chiu C.C., Lin C.H., and Fang K. Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis. Apoptosis 10 (2005) 643-650
54. Myung K., Datta A., and Kolodner R.D. Suppression of spontaneous chromosomal rearrangements by S phase checkpoint functions in Saccharomyces cerevisiae. Cell 104 (2001) 397-408
55. Myung K., and Kolodner R.D. Suppression of genome instability by redundant S-phase checkpoint pathways in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 4500-4507
56. Knauf J.A., Ouyang B., Knudsen E.S., Fukasawa K., Babcock G., and Fagin J.A. Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. J. Biol. Chem. 281 (2006) 3800-3809
57. Abbott D.W., and Holt J.T. Mitogen-activated protein kinase kinase 2 activation is essential for progression through the G2/M checkpoint arrest in cells exposed to ionizing radiation. J. Biol. Chem. 274 (1999) 2732-2742
58. Rios-Doria J., Fay A., Velkova A., and Monteiro A.N. DNA damage response: determining the fate of phosphorylated histone H2AX. Cancer Biol. Ther. 5 (2006) 142-144
59. Stucki M., and Jackson S.P. GammaH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes. DNA Repair (Amst.) 5 (2006) 534-543
60. Brunet A., Pages G., and Pouyssegur J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 9 (1994) 3379-3387
61. Cowley S., Paterson H., Kemp P., and Marshall C.J. Activation of MAP kinasekinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77 (1994) 841-852
62. Mansour S.J., Matten W.T., Hermann A.S., Candia J.M., Rong S., Fukasawa K., Vande Woude G.F., and Ahn N.G. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265 (1994) 966-970
63. Kim D., Cheng G.Z., Lindsley C.W., Yang H., and Cheng J.Q. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr. Opin. Investig. Drugs 6 (2005) 1250-1258 (Review)
64. Sawyer J.R., Lukacs J.L., Munshi N., Desikan K.R., Singhal S., Mehta J., Siegel D., Shaughnessy J., and Barlogie B. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 92 (1998) 4269-4278